General Anesthesia Drugs Market Growth, Size, Trends, Price, Revenue, Demand and Future Outlook
General Anesthesia Drugs Market Size- By Drug Type, By Route of Administration, By Surgery Type, By End User - Regional Outlook, Competitive Strategies and Segment Forecast to 2033
| Published: Nov-2022 | Report ID: PHAR2211 | Pages: 1 - 230 | Formats*: |
| Category : Pharmaceutical | |||
General Anesthesia Drugs Market Introduction and Overview
According to SPER Market Research, the Global General Anesthesia Drugs Market is estimated to reach USD 8.59 billion by 2033 with a CAGR of 3.73%.
The report includes an in-depth analysis of the Global General Anesthesia Drugs Market, including market size and trends, product mix, distribution channels, and supplier analysis. General anesthesia drugs are medications used to induce a reversible state of unconsciousness and immobility in patients during surgical procedures. These drugs act on the central nervous system, suppressing consciousness, pain perception, and muscle reflexes. They are administered by trained healthcare professionals and help ensure patient comfort, facilitate surgery, and maintain vital signs throughout the procedure.
- January 2022: Akorn Operating Company LLC has agreed to sell seven branded ophthalmic products to Laboratories Théa SAS. Théa will be able to add Akorn-branded medicines to its portfolio, including Akten (lidocaine HCl ophthalmic gel), a local anaesthetic recommended for ocular surface anaesthesia during ophthalmologic operations, as a result of the strategic move.
- Propofol is one of the most regularly used general anaesthetics in surgery and is used as a sedative in the ICU for critical care patients (particularly those with COVID-19). It is used to start and keep procedural sedation, general anaesthesia, and so on going. The US Food and Drug Administration authorised the use of Fresenius Propoven 2% emulsion to sustain sedation in COVID-19 patients (16 years and older) requiring mechanical breathing in June 2020.
Market Opportunities and Challenges
One of the significant market opportunities in the global general anesthesia drugs market is the increasing demand for outpatient surgeries. As advancements in medical technology and surgical techniques continue to evolve, there is a growing trend towards performing surgeries on an outpatient basis. This creates a need for shorter-acting and rapid-recovery anesthesia drugs that allow patients to recover quickly and safely, enabling them to return home the same day. Meeting this demand presents an opportunity for drug manufacturers to develop and market anesthesia drugs specifically tailored for outpatient procedures.
The possible risk of side effects and problems associated with anaesthesia administration is one of the primary issues in the worldwide general anaesthesia medications market. Respiratory depression, cardiovascular instability, allergic responses, and post-operative cognitive impairment are among dangers of anaesthesia. To ensure patient safety and minimise these hazards, rigorous patient evaluation, adequate medication selection, precise dose determination, and constant monitoring throughout the anaesthesia procedure are required. Developing and improving anaesthesia medications with enhanced safety profiles while minimising possible consequences is a major issue for industry companies.
-008182814082023.jpg)
Market Competitive Landscape
The anaesthesia pharmaceuticals industry is quite competitive, with numerous large competitors. However, as medicine approvals increase, mid-sized to smaller firms are growing their market position by releasing novel components at lower prices. The key players in the global General Anesthesia Drugs market include Akorn, Novartis AG, Glaxo SmithKline Plc, Fresenius Se & Co KGaA, F. Hoffmann- La Roche, Astra Zeneca Plc, Piramal Enterprises Ltd., Pfizer Inc., Par Pharmaceuticals, Merck & Co Inc., Sanofi, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others.
Scope of the Report:
| Report Metric | Details |
| Market size available for years | 2019-2033 |
| Base year considered | 2022 |
| Forecast period | 2023-2033 |
| Segments covered | By Product, By Mobility, By Mode, By End User |
| Regions covered | Asia-Pacific, Latin America, Europe, Middle East and Africa, North America |
| Companies Covered | Akorn, Novartis AG, Gilead Science Inc., Glaxo SmithKline Plc, Fresenius Se & Co KGaA, F. Par Pharmaceuticals, Hoffmann- La Roche, Sanofi, Merck & Co Inc., Astra Zeneca Plc, Baxter International Inc., Apotex, Heritage Pharmaceutical Inc., Pfizer Inc., Piramal Enterprises Ltd., Hikma Pharmaceuticals Plc, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others |
COVID-19 Impact on Global General Anesthesia Drugs Market
The worldwide anaesthesia medication industry was significantly impacted by COVID-19. Because of the interruption in surgical operations, non-emergency surgeries were postponed or cancelled, resulting in lower demand for anaesthesia medicines. To reduce the danger of viral transmission, healthcare practitioners moved to alternate anaesthesia procedures such as regional anaesthesia and local anaesthesia, affecting demand for general anaesthesia medicines. Supply chain interruptions induced by lockdown measures and manufacturing issues resulted in anaesthesia medicine shortages, affecting patient care and surgical operations even more. These impacts emphasise the difficulties that the anaesthesia medication market experienced during the epidemic.
Key Target Audience
- Academic and Research Institutions
- Healthcare Providers
- Hospitals and Surgical Centres
- Regulatory Authorities
- Anesthesiologists and Anesthesia Providers
- Pharmaceutical Companies
- Medical Device Manufacturers
- Others
Our in-depth analysis of the General Anesthesia Drugs Market includes the following segments:
| By Drug Type: |
|
| By Route of Administration: |
|
| By Surgery Type: |
|
| By End User: |
|
Key Topics Covered in the Report
- Global General Anesthesia Drugs Market Size (FY’2023-FY’2033)
- Outline of Global General Anesthesia Drugs Market
- Segmentation of Global General Anesthesia Drugs Market By Drug Type (Desflurane, Midazolam, Sevoflurane, Propofol, Dexmedetomidine Remifentanil, Others)
- Segmentation of Global General Anesthesia Drugs Market By Route of Administration (Intravenous, Inhalation)
- Segmentation of Global General Anesthesia Drugs Market By Surgery Type (Cancer Surgery, Heart Surgery, Knee and Hip Replacements, General Surgery)
- Segmentation of Global General Anesthesia Drugs Market By End User (Ambulatory Surgical Centres, Hospitals)
- Statistical Snap of Global General Anesthesia Drugs Market
- Expansion Analysis of Global General Anesthesia Drugs Market
- Problems and Challenges in Global General Anesthesia Drugs Market
- Competitive View of the Global General Anesthesia Drugs Market
- Effects of Demonetization and COVID-19 on Global General Anesthesia Drugs Market
- Details on Current Investment in Global General Anesthesia Drugs Market
- Competitive Analysis of Global General Anesthesia Drugs Market
- Prominent Players in the Global General Anesthesia Drugs Market
- SWOT Analysis of Global General Anesthesia Drugs Market
- Global General Anesthesia Drugs Market Future Projections and Outlook (FY’2023-FY’2033)
- Recommendations from Analyst
1. Introduction
1.1. Scope of the report1.2. Market segment analysis
2. Research Methodology
2.1. Research data source
2.1.1. Secondary Data2.1.2. Primary Data2.1.3. SPER’s internal database2.1.4. Premium insight from KOL’s
2.2. Market size estimation
2.2.1. Top-down and Bottom-up approach
2.3. Data triangulation
3. Executive Summary
4. Market Dynamics
4.1. Driver, Restraint, Opportunity and Challenges analysis
4.1.1. Drivers4.1.2. Restraints4.1.3. Opportunities
4.1.4. Challenges
4.2. COVID-19 Impacts of the Global General Anesthesia Drugs Market
5. Market variable and outlook
5.1. SWOT Analysis
5.1.1. Strengths5.1.2. Weaknesses5.1.3. Opportunities5.1.4. Threats
5.2. PESTEL Analysis
5.2.1. Political Landscape5.2.2. Economic Landscape5.2.3. Social Landscape5.2.4. Technological Landscape
5.2.5. Environmental Landscape5.2.6. Legal Landscape
5.3. PORTER’s Five Forces
5.3.1. Bargaining power of suppliers5.3.2. Bargaining power of buyers5.3.3. Threat of Substitute5.3.4. Threat of new entrant5.3.5. Competitive rivalry
5.4. Heat Map Analysis
6. Competitive Landscape
6.1. Global General Anesthesia Drugs Market Manufacturing Base Distribution, Sales Area, Product Type6.2. Mergers & Acquisitions, Partnerships, Product Launch, and Collaboration in Global General Anesthesia Drugs Market
7. Global General Anesthesia Drugs Market, By Drug Type (USD Million)
7.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Drug Type, 2023-20337.2. Desflurane7.3. Dexmedetomidine7.4. Midazolam7.5. Propofol7.6. Remifentanil7.7. Sevoflurane7.8. Others
8. Global General Anesthesia Drugs Market, By Route of Administration (USD Million)
8.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Route of Administration, 2023-20338.2. Inhalation8.3. Intravenous
9. Global General Anesthesia Drugs Market, By Surgery Type (USD Million)
9.1. Global General Anesthesia Drugs Market Value Share and Forecast, By Surgery Type, 2023-20339.2. Cancer Surgery9.3. General Surgery9.4. Heart Surgery9.5. Knee and Hip Replacements
10. Global General Anesthesia Drugs Market, By End User (USD Million)
10.1. Global General Anesthesia Drugs Market Value Share and Forecast, By End User, 2023-203310.2. Ambulatory Surgical Centres10.3. Hospitals
11. Global General Anesthesia Drugs Market Forecast, 2019-2033 (USD Million)
11.1. Global General Anesthesia Drugs Market Size and Market Share
12. Global General Anesthesia Drugs Market, By Drug Type, 2019-2033 (USD Million)
12.1. Global General Anesthesia Drugs Market Size and Market Share By Drug Type (2019-2026)12.2. Global General Anesthesia Drugs Market Size and Market Share By Drug Type (2027-2033)
13. Global General Anesthesia Drugs Market, By Route of Administration, 2019-2033 (USD Million)
13.1. Global General Anesthesia Drugs Market Size and Market Share By Route of Administration (2019-2026)13.2. Global General Anesthesia Drugs Market Size and Market Share By Route of Administration (2027-2033)
14. Global General Anesthesia Drugs Market, By Surgery Type, 2019-2033 (USD Million)
14.1. Global General Anesthesia Drugs Market Size and Market Share By Surgery Type (2019-2026)14.2. Global General Anesthesia Drugs Market Size and Market Share By Surgery Type (2027-2033)
15. Global General Anesthesia Drugs Market, By End User, 2019-2033 (USD Million)
15.1. Global General Anesthesia Drugs Market Size and Market Share By End User (2019-2026)15.2. Global General Anesthesia Drugs Market Size and Market Share By End User (2027-2033)
16. Global General Anesthesia Drugs Market, By Region, 2019-2033 (USD Million)
16.1. Global General Anesthesia Drugs Market Size and Market Share By Region (2019-2026)16.2. Global General Anesthesia Drugs Market Size and Market Share By Region (2027-2033)16.3. Asia-Pacific
16.3.1. Australia16.3.2. China16.3.3. India16.3.4. Japan16.3.5. South Korea16.3.6. Rest of Asia-Pacific
16.4. Europe
16.4.1. France16.4.2. Germany16.4.3. Italy16.4.4. Spain16.4.5. United Kingdom16.4.6. Rest of Europe
16.5. Middle East and Africa
16.5.1. Kingdom of Saudi Arabia16.5.2. United Arab Emirates16.5.3. Rest of Middle East & Africa
16.6. North America
16.6.1. Canada16.6.2. Mexico16.6.3. United States
16.7. Latin America
16.7.1. Argentina16.7.2. Brazil16.7.3. Rest of Latin America
17. Company Profile
17.1. Abbott Laboratories
17.1.1. Company details17.1.2. Financial outlook17.1.3. Product summary17.1.4. Recent developments
17.2. Abbvie
17.2.1. Company details17.2.2. Financial outlook17.2.3. Product summary17.2.4. Recent developments
17.3. Akorn
17.3.1. Company details17.3.2. Financial outlook17.3.3. Product summary17.3.4. Recent developments
17.4. Apotex
17.4.1. Company details17.4.2. Financial outlook17.4.3. Product summary17.4.4. Recent developments
17.5. Astra Zeneca Plc
17.5.1. Company details17.5.2. Financial outlook17.5.3. Product summary17.5.4. Recent developments
17.6. Baxter International Inc.
17.6.1. Company details17.6.2. Financial outlook17.6.3. Product summary17.6.4. Recent developments
17.7. Bayer AG
17.7.1. Company details17.7.2. Financial outlook17.7.3. Product summary17.7.4. Recent developments
17.8. F. Hoffmann- La Roche
17.8.1. Company details17.8.2. Financial outlook17.8.3. Product summary17.8.4. Recent developments
17.9. Fresenius Se & Co KgaA
17.9.1. Company details17.9.2. Financial outlook17.9.3. Product summary17.9.4. Recent developments
17.10. Gilead Science Inc.
17.10.1. Company details17.10.2. Financial outlook17.10.3. Product summary17.10.4. Recent developments
17.11. Glaxo SmithKline Plc
17.11.1. Company details17.11.2. Financial outlook17.11.3. Product summary17.11.4. Recent developments
17.12. Heritage Pharmaceutical Inc.
17.12.1. Company details17.12.2. Financial outlook17.12.3. Product summary17.12.4. Recent developments
17.13. Hikma Pharmaceuticals Plc
17.13.1. Company details17.13.2. Financial outlook17.13.3. Product summary17.13.4. Recent developments
17.14. Merck & Co Inc.
17.14.1. Company details17.14.2. Financial outlook17.14.3. Product summary17.14.4. Recent developments
17.15. Novartis AG
17.15.1. Company details17.15.2. Financial outlook17.15.3. Product summary17.15.4. Recent developments
17.16. Par Pharmaceuticals
17.16.1. Company details17.16.2. Financial outlook17.16.3. Product summary17.16.4. Recent developments
17.17. Pfizer Inc.
17.17.1. Company details17.17.2. Financial outlook17.17.3. Product summary17.17.4. Recent developments
17.18. Piramal Enterprises Ltd.
17.18.1. Company details17.18.2. Financial outlook17.18.3. Product summary17.18.4. Recent developments
17.19. Sanofi
17.19.1. Company details17.19.2. Financial outlook17.19.3. Product summary17.19.4. Recent developments
17.20. Teva Pharmaceuticals
17.20.1. Company details17.20.2. Financial outlook17.20.3. Product summary17.20.4. Recent developments
17.21. Others
18. List of Abbreviations
19. Reference Links
20. Conclusion
21. Research Scope
SPER Market Research’s methodology uses great emphasis on primary research to ensure that the market intelligence insights are up to date, reliable and accurate. Primary interviews are done with players involved in each phase of a supply chain to analyze the market forecasting. The secondary research method is used to help you fully understand how the future markets and the spending patterns look likes.
The report is based on in-depth qualitative and quantitative analysis of the Product Market. The quantitative analysis involves the application of various projection and sampling techniques. The qualitative analysis involves primary interviews, surveys, and vendor briefings. The data gathered as a result of these processes are validated through experts opinion. Our research methodology entails an ideal mixture of primary and secondary initiatives.
Frequently Asked Questions About This Report
The General Anesthesia Drugs Market is projected to reach USD 8.59 billion by 2033, growing at a CAGR of 3.73% during the forecast period.
The General Anesthesia Drugs Market grew in market size from 2023. The Market is expected to reach USD 8.59 billion by 2033, at a CAGR of 3.73% during the forecast period.
The General Anesthesia Drugs Market CAGR of 3.73% during the forecast period.
You can get the sample pages by clicking the link - Click Here
The General Anesthesia Drugs Market size is USD 8.59 billion from 2023 to 2033.
The Anesthesia Drug Market segment is Covered By Drug Type, By Route of Administration, By Surgery Type, By End User.
The North America region is anticipated to have the highest market share in the Anesthesia Drug Market.
The key players in the market include Companies Covered Akorn, Novartis AG, Gilead Science Inc., Glaxo SmithKline Plc, Fresenius Se & Co KgaA, F. Hoffmann- La Roche, Astra Zeneca Plc, Piramal Enterprises Ltd., Pfizer Inc., Par Pharmaceuticals, Merck & Co Inc., Heritage Pharmaceutical Inc., Hikma Pharmaceuticals Plc, Baxter International Inc., Apotex, Sanofi, Teva Pharmaceuticals, Bayer AG, Abbvie, Abbott Laboratories, Others.
More consumers are turning to internet shops to make purchases, pay bills, and consult with doctors. This shift in consumer behaviour is projected to propel the general anaesthetic pharmaceutical market in the coming years.
PLACE AN ORDER
Year End Discount
Sample Report
Pre-Purchase Inquiry
NEED CUSTOMIZATION?
Request CustomizationCALL OR EMAIL US
100% Secure Payment
Related Reports
Have a glance of the Report
Our Global Clients
Our data-driven insights have influenced the strategy of 200+ reputed companies across the globe.
